Company Overview
| Stock Name | Circ |
|---|---|
| Stock Code | 01763 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 主要從事診斷及治療用放射性藥品及醫用和工業用放射源產品的研究、開發、製造及銷售,並提供輻照滅菌服務及伽瑪射線輻照裝置的設計、製造及安裝的EPC服務,以及向醫院及其他醫療機構提供獨立醫學檢驗實驗室服務。 |
| Listing Date | 2018-07-06 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 北京市西城區復興門外大街A2號6層611室 |
| Business Address (Hong Kong) | 皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | china-isotope.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 21.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2018-06-22 to 2018-06-27 |
| Global Offering Shares | 79,968,700 shares |
| HK Public Offer Shares (Initial) | 7,997,200 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 71,971,500 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 319,874,800 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 48.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,727,323,920 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.34B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +600% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 7,741,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利约人民币475.6百万元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2015 | 2016 | 2017 |
|---|---|---|---|
| Profit for the year | 410,382 | 434,502 | 475,638 |
Balance Sheet
| Item | 2015 | 2016 | 2017 |
|---|---|---|---|
| Cash and cash equivalents | 711,089 | 1,003,217 | 1,478,833 |
| Trade and bills receivables | 1,064,748 | 1,214,857 | 1,507,234 |
| Inventories | 188,038 | 225,734 | 263,002 |
| Total current assets | 2,108,336 | 2,574,788 | 3,459,942 |
| Total current liabilities | 1,404,268 | 1,952,513 | 1,916,239 |
| Total equity | 1,353,650 | 1,473,458 | 2,446,334 |
| Equity attributable to owners | 847,660 | 927,522 | 1,868,944 |
| Interest-bearing borrowings | 60,000 | 110,183 | 480,000 |
Cash Flow Statement
| Item | 2015 | 2016 | 2017 |
|---|---|---|---|
| Net cash from operating activities | 389,536 | 457,633 | 429,760 |
| Net cash from investing activities | -76,032 | -150,378 | -437,472 |
| Net cash from financing activities | -470,988 | -40,898 | 228,367 |
| Net increase in cash | -157,484 | 266,357 | 220,655 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 20.1 |
|---|---|
| First Day Open | HK$ 20.0 |
| First Day Change | -6.94% |
| First Day Volume | 29619000.0 |
| First Day Turnover | 599830000.0 |
| Use of Proceeds | 1、約41.7%所得款項凈額或約671.17百萬港元預期用于投資分別位于河北省香河及四川省成都市的兩個顯像診斷及治療用放射性藥品生產及研發基地,以提升我們的生產及研發能力;
2、約4.7%所得款項凈額或約75.65百萬港元預期用于建立四間生產及分銷附屬公司,以主要于中國生產及分銷锝[99mTc]標記注射液及氟[18F]脫氧葡糖注射液;
3、約5.9%所得款項凈額或約94.96百萬港元預期用于在廣東省深圳市及安徽省桐城市建立新生產設施,以擴充尿素呼氣試驗藥盒及測試儀的產能;
4、約17.7%所得款項凈額或約284.88百萬港元預期用于投資研發多種顯像診斷及治療用放射性藥品、放射源產品的原材料、醫用放射性同位素及尿素呼氣試驗產品及相關原材料;
5、約20.0%所得款項凈額或約321.90百萬港元預期用于選擇性收購;
6、約10.0%所得款項凈額或約160.95百萬港元預期用作營運資金及一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
中国国际金融香港证券有限公司 CE AEN894
Joint Lead Managers (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 北京工业发展投资管理有限公司 | 235,418,400 HKD | — | 13.63% | — | 6 months | 2019-01-06 |
| 2 | 上海医药(香港)投资有限公司 | 172,929,600 HKD | — | 10.01% | — | 6 months | 2019-01-06 |
| 3 | 通程控股有限公司 | 257,178,240 HKD | — | 14.89% | — | 6 months | 2019-01-06 |
| 4 | 中国国有企业结构调整基金股份有限公司 | 176,148,000 HKD | — | 10.20% | — | 6 months | 2019-01-06 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 孟琰彬 | — |
| Company Secretary | 吳來水、甘美霞 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 中核集團直接及間接透過原子能院、核動力院、中核基金、四〇四公司及寶原投資持有本公司全球發售後已發行股本總額約73.83%(假設超額配股權未獲行使),為控股股東。 |
|---|




